Medical Nitrous Oxide (Nippon Gases Scandinavia)
Active ingredient: Nitrous oxide (N₂O) — Dinitrogen monoxide
Medical nitrous oxide (N₂O), marketed by Nippon Gases Scandinavia, is a colorless medicinal gas with analgesic (pain-relieving) and anxiolytic (anxiety-reducing) properties. It has been used in clinical medicine for over 170 years and remains one of the most widely used anesthetic agents worldwide. Nitrous oxide is primarily employed for procedural pain relief, labor analgesia, dental sedation, and as an adjunct to general anesthesia. When administered as a 50:50 mixture with oxygen, it provides rapid-onset pain relief while allowing the patient to remain conscious and cooperative.
Quick Facts
Key Takeaways
- Medical nitrous oxide is a well-established analgesic gas used for over 170 years, providing rapid pain relief within 2–5 minutes of inhalation with equally rapid offset after discontinuation.
- It is most commonly administered as a 50:50 N₂O/O₂ mixture (Entonox) for labor pain, dental procedures, emergency analgesia, and minor surgical procedures, and is listed on the WHO Model List of Essential Medicines.
- Nitrous oxide is contraindicated in patients with pneumothorax, bowel obstruction, middle ear conditions, and known vitamin B12 deficiency due to its gas-expanding and B12-inactivating properties.
- Side effects are generally mild and self-limiting (nausea, dizziness, euphoria), but prolonged or repeated exposure can cause serious vitamin B12 depletion leading to megaloblastic anemia and peripheral neuropathy.
- Healthcare facilities must ensure proper scavenging systems and workplace exposure monitoring, as chronic occupational exposure poses reproductive and neurological health risks to staff.
What Is Medical Nitrous Oxide and What Is It Used For?
Medical nitrous oxide, commonly known as "laughing gas," is a colorless, odorless-to-sweet-smelling gas with the chemical formula N₂O. It has been a cornerstone of clinical analgesia and anesthesia since its first use in dentistry by Horace Wells in 1844. Today, it remains one of the most frequently used anesthetic and analgesic agents in healthcare settings worldwide and is included on the World Health Organization (WHO) Model List of Essential Medicines.
Nippon Gases Scandinavia supplies medical-grade nitrous oxide in compressed gas cylinders for healthcare use. The gas meets the stringent purity requirements of the European Pharmacopoeia (minimum 98.0% v/v N₂O). It is supplied at high pressure in cylinders that are color-coded according to international standards (blue body for nitrous oxide in most regions). The product is manufactured under Good Manufacturing Practice (GMP) conditions to ensure consistent pharmaceutical quality.
Nitrous oxide works through several complementary pharmacological mechanisms. It acts primarily as an NMDA (N-methyl-D-aspartate) receptor antagonist, which accounts for its analgesic properties. Additionally, it modulates opioid receptors, particularly the kappa-opioid pathway, and activates descending noradrenergic inhibitory pathways in the spinal cord. These combined mechanisms produce analgesia, anxiolysis (anxiety reduction), and mild euphoria without causing significant loss of consciousness at sub-anesthetic concentrations.
Common Clinical Indications
Medical nitrous oxide is used across a wide range of clinical settings. Its versatility and favorable safety profile make it suitable for both adults and children in various situations:
- Labor and delivery analgesia: As a 50:50 N₂O/O₂ mixture, it is one of the most widely used forms of labor pain relief worldwide. The mother self-administers the gas through a demand valve, inhaling during contractions. It does not interfere with uterine contractility, does not require intravenous access, and allows the mother to remain conscious and mobile.
- Dental procedures: Nitrous oxide sedation is a mainstay of pediatric and adult dentistry, particularly for anxious patients. It reduces fear and pain perception while allowing the patient to cooperate with the dentist. Concentrations typically range from 25% to 50% N₂O in oxygen.
- Emergency medicine: Pre-hospital and emergency department use for acute pain from fractures, burns, wound suturing, dislocations, and other painful injuries. Its rapid onset and offset make it ideal for emergency settings where quick analgesia is needed.
- Minor surgical and diagnostic procedures: Including wound dressing changes, removal of drains, biopsies, lumbar punctures, and endoscopic procedures. It provides adequate pain relief and anxiolysis for many procedures that might otherwise require intravenous sedation.
- Pediatric procedures: Particularly valuable in children for venipuncture, laceration repair, fracture reduction, and other brief painful procedures. Children generally respond well to nitrous oxide, and the non-invasive administration route (inhalation) is particularly advantageous in this population.
- Adjunct to general anesthesia: At concentrations of 50–70%, nitrous oxide reduces the required dose of other anesthetic agents (the so-called "second gas effect" and MAC-reduction), providing a smoother induction and potentially faster recovery.
What Should You Know Before Using Medical Nitrous Oxide?
While medical nitrous oxide has an excellent safety record spanning more than a century, there are specific medical conditions and circumstances that make its use inappropriate or require special precautions. A thorough patient assessment is essential before administration. Healthcare providers should conduct a focused clinical evaluation to identify contraindications and risk factors before initiating nitrous oxide therapy.
Contraindications
Nitrous oxide must not be used in the following conditions, as it could cause serious harm:
- Pneumothorax or suspected pneumothorax: Nitrous oxide is 34 times more soluble in blood than nitrogen. It diffuses into air-filled spaces faster than nitrogen can diffuse out, causing expansion. In a pneumothorax, this can rapidly worsen lung collapse and become life-threatening.
- Bowel obstruction: The same gas-expansion mechanism can distend obstructed bowel loops, increasing the risk of perforation and worsening patient discomfort. Any condition with trapped gas in the abdomen is a contraindication.
- Middle ear surgery or conditions: Gas expansion in the middle ear space can disrupt surgical repairs, displace tympanic membrane grafts, or cause significant pain and hearing damage.
- Maxillofacial injuries with suspected fractures near air sinuses: Risk of subcutaneous emphysema or orbital complications from gas expansion in fractured sinus cavities.
- Recent intraocular gas injection: Patients who have had vitreoretinal surgery using intraocular gas (SF6 or C3F8) must not receive nitrous oxide, as it can expand the intraocular gas bubble and cause blindness. This contraindication persists for up to 3 months after surgery.
- Decompression sickness (the bends): Nitrous oxide would expand nitrogen bubbles in the blood and tissues, worsening the condition.
- Severe chronic obstructive pulmonary disease (COPD) with air trapping: Risk of bullae expansion in emphysematous lungs.
- Significantly impaired level of consciousness: Patients who cannot protect their airway or cooperate with self-administration should not receive nitrous oxide outside of a controlled anesthesia setting.
Warnings and Precautions
Special caution is required in the following situations:
- Vitamin B12 deficiency: Nitrous oxide irreversibly oxidizes the cobalt ion in vitamin B12 (cobalamin), inactivating it. This impairs methionine synthase and thymidylate synthase, disrupting DNA synthesis and myelin maintenance. Patients with existing B12 deficiency, vegans, elderly patients with poor nutrition, or those with pernicious anemia are at significantly increased risk of neurological complications including subacute combined degeneration of the spinal cord.
- Prolonged or repeated exposure: Even in patients with normal B12 levels, prolonged administration (more than 6 hours continuously) or repeated exposure within short intervals can deplete functional B12 stores. Healthcare providers should monitor for signs of B12 deficiency (tingling, numbness, weakness) in patients receiving repeated nitrous oxide treatments.
- Diffusion hypoxia: When nitrous oxide administration is discontinued, the rapid elimination of N₂O from blood into the alveoli can dilute alveolar oxygen, temporarily causing hypoxia. This is prevented by administering 100% oxygen for 3–5 minutes after discontinuing nitrous oxide (the "washout" period).
- Occupational exposure: Healthcare workers, particularly in obstetric, dental, and operating room settings, may be chronically exposed to trace levels of nitrous oxide. Effective scavenging systems and adequate room ventilation are mandatory. Recommended occupational exposure limits are typically 25–100 ppm (time-weighted average), varying by jurisdiction.
- Substance abuse potential: Nitrous oxide has a recognized potential for recreational misuse. Healthcare facilities must maintain proper storage security and accounting of medical gas supplies.
Pregnancy and Breastfeeding
Nitrous oxide crosses the placenta freely and reaches equilibrium between maternal and fetal blood within minutes. The clinical implications differ based on the context of use:
Labor analgesia: The use of 50% N₂O/50% O₂ (Entonox) during active labor is considered safe and is widely practiced worldwide. Large observational studies and decades of clinical experience show no increase in neonatal adverse outcomes when used during labor. The gas is rapidly eliminated from both mother and neonate after birth. The American College of Obstetricians and Gynecologists (ACOG) and numerous international obstetric guidelines support its use as a labor analgesic option.
First trimester: Based on animal studies showing potential teratogenic effects at very high concentrations and prolonged exposure durations, nitrous oxide is generally avoided for elective procedures during the first trimester of pregnancy as a precautionary measure. However, the risk from brief clinical exposure is considered very low.
Breastfeeding: Nitrous oxide is eliminated almost entirely through the lungs within minutes of discontinuation. It does not accumulate in breast milk in clinically significant amounts. Breastfeeding can be resumed immediately after nitrous oxide administration, and no interruption in breastfeeding is necessary.
How Does Medical Nitrous Oxide Interact with Other Drugs?
Drug interactions with nitrous oxide primarily involve two mechanisms: (1) pharmacodynamic potentiation of CNS-depressant effects, and (2) interference with folate-dependent metabolic pathways through B12 inactivation. Understanding these interactions is critical for safe clinical use, as many patients undergoing procedures will be receiving concomitant medications.
Major Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Methotrexate | Pharmacodynamic — both impair folate metabolism | Increased risk of severe megaloblastic anemia and bone marrow suppression | Avoid prolonged N₂O exposure; monitor blood counts if unavoidable |
| Opioids (morphine, fentanyl, codeine) | Pharmacodynamic — additive CNS depression | Enhanced sedation, respiratory depression, risk of apnea | Reduce opioid doses; monitor respiratory rate and oxygen saturation closely |
| Benzodiazepines (midazolam, diazepam) | Pharmacodynamic — additive CNS depression | Excessive sedation, airway compromise, prolonged recovery | Use lower N₂O concentrations; ensure airway monitoring |
| Bleomycin | Pharmacodynamic — increased pulmonary oxidative stress | Potentially increased risk of pulmonary fibrosis and ARDS | Avoid nitrous oxide in patients who have received bleomycin; use alternative analgesics |
Minor Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Alcohol | Additive CNS depression | Enhanced sedation and impaired coordination | Assess sobriety before administration; use reduced N₂O concentration |
| Antihistamines (sedating types) | Additive sedation | Mild to moderate increased drowsiness | Inform patient of possible increased drowsiness; monitor |
| Other volatile anesthetics (sevoflurane, isoflurane) | Pharmacodynamic — MAC reduction | Reduces the required concentration of the volatile agent (desired effect in anesthesia) | Adjust volatile agent concentration accordingly (standard anesthesia practice) |
| Proton pump inhibitors (long-term use) | Both may reduce B12 absorption/function | Combined risk of B12 depletion | Check B12 levels before prolonged or repeated N₂O use |
Nitrous oxide does not have significant interactions with most common medications including antibiotics, antihypertensives, antidiabetics, or inhaled bronchodilators. Its rapid elimination through the lungs means that pharmacokinetic interactions (absorption, distribution, metabolism, excretion) are minimal. The primary concern remains pharmacodynamic interactions involving CNS depression and B12 metabolism.
What Is the Correct Dosage of Medical Nitrous Oxide?
Unlike most medications, nitrous oxide dosing is largely self-regulated by the patient through a demand-valve delivery system. This inherent safety feature means that if the patient becomes overly sedated, they release the mouthpiece or mask, stopping gas flow and allowing rapid recovery. The concentration used depends on the clinical indication, setting, and patient response. There are no weight-based dose calculations required for standard analgesic use.
Adults
Procedural Analgesia (Entonox — 50% N₂O / 50% O₂)
Self-administered via demand valve through facemask or mouthpiece. Patient inhales the gas mixture during periods of pain (e.g., contractions during labor, during wound care procedures). Onset of effect within 2–5 minutes. Continue as needed throughout the procedure. Administer 100% oxygen for 3–5 minutes after cessation to prevent diffusion hypoxia.
Dental Sedation
Administered via nasal hood by trained dental professional. Begin with 100% oxygen for 2–3 minutes. Titrate N₂O upward in 5–10% increments every 1–2 minutes, typically achieving adequate sedation at 25–50% N₂O. Maximum recommended concentration for dental use is generally 50% (some guidelines allow up to 70% in specialist settings). Must always maintain a minimum of 30% oxygen.
Adjunct to General Anesthesia
50–70% N₂O in oxygen, delivered via anesthesia breathing circuit. Administered by an anesthesiologist as part of a balanced anesthetic technique. Reduces the required dose (MAC) of concomitant volatile anesthetic agents by approximately 0.5 MAC equivalent.
Children
Pediatric Procedural Analgesia (age 4 years and above)
Entonox (50% N₂O / 50% O₂) via demand valve or continuous flow system with appropriate pediatric facemask. Children typically need 2–3 minutes of coaching before the procedure to learn the inhalation technique. Same concentrations as adults; self-administration provides an inherent safety limit. For younger children who cannot manage a demand valve, continuous-flow delivery with appropriate scavenging may be used under direct medical supervision.
Pediatric Dental Sedation
Nasal hood delivery, starting with 100% oxygen and titrating N₂O in 10% increments. Target concentrations typically 30–40% N₂O. Minimum oxygen concentration: 30%. Extra attention to monitoring is required, and the treating dentist should have specific training in pediatric sedation techniques.
Elderly Patients
Elderly (65 years and above)
Same concentrations as younger adults. However, elderly patients may be more sensitive to sedative effects and may have reduced B12 stores, increasing the risk of neurological complications with prolonged use. Start with lower concentrations and titrate upward. Avoid prolonged or repeated administration without checking vitamin B12 status. Monitor closely for excessive sedation and ensure post-procedure observation until full recovery.
Missed Dose
The concept of a "missed dose" does not apply to nitrous oxide, as it is an on-demand analgesic administered only during procedures or episodes of acute pain. There is no scheduled dosing regimen. Each administration episode is independent, and the gas is used only as needed during the clinical encounter. If a planned procedure involving nitrous oxide is postponed, no compensatory action is required.
Overdose
True overdose with self-administered nitrous oxide is uncommon due to the inherent safety of the demand-valve system: if the patient becomes too sedated, they drop the mouthpiece and gas delivery stops. However, overdose can occur in certain circumstances:
- Administration of high concentrations with inadequate oxygen: If the oxygen fraction falls below 21%, hypoxia can result. Modern anesthesia machines have safety interlocks (hypoxic guard systems) to prevent this, but older equipment or improperly configured systems may not.
- Prolonged continuous administration: Extended use exceeding several hours may lead to symptomatic vitamin B12 depletion, bone marrow suppression, and neurological toxicity.
Management of overexposure: Discontinue nitrous oxide immediately. Administer 100% oxygen via face mask. Monitor oxygen saturation with pulse oximetry. Support airway and ventilation as needed. In cases of prolonged exposure with suspected B12 depletion, consider vitamin B12 (hydroxocobalamin) supplementation and monitor complete blood count. Symptoms of acute overexposure (sedation, dizziness, nausea) typically resolve within 5–10 minutes of cessation due to the rapid elimination of N₂O from the lungs.
What Are the Side Effects of Medical Nitrous Oxide?
Medical nitrous oxide has a favorable side effect profile when used appropriately for short-duration procedures. Most adverse effects are mild, dose-related, and rapidly reversible upon discontinuation. However, certain serious complications can arise with prolonged or repeated exposure. The side effect frequency classifications below are based on data from the European Medicines Agency (EMA) Summary of Product Characteristics and published clinical literature.
Very Common (>1 in 10 patients)
- Euphoria and lightheadedness (the "laughing gas" effect)
- Tingling or numbness in extremities (paresthesia) during inhalation
- Altered sound perception (sounds may appear distant or muffled)
Common (1 in 10 to 1 in 100 patients)
- Nausea
- Vomiting
- Dizziness and vertigo
- Headache
- Excessive sedation or drowsiness
- Dry mouth
Uncommon (1 in 100 to 1 in 1,000 patients)
- Abdominal distension
- Middle ear pressure changes (ear discomfort)
- Agitation, anxiety, or dysphoria (particularly in children)
- Vivid dreams or hallucinations
- Diffusion hypoxia (if oxygen washout omitted after cessation)
Rare (<1 in 1,000 patients)
- Megaloblastic anemia (with prolonged/repeated exposure)
- Subacute combined degeneration of the spinal cord (peripheral neuropathy, loss of proprioception)
- Bone marrow suppression (agranulocytosis, aplastic crisis)
- Pneumothorax expansion (if administered despite contraindication)
- Severe allergic reaction (extremely rare; true allergy to N₂O is virtually undocumented)
The neurological complications associated with B12 inactivation deserve particular attention. Subacute combined degeneration of the spinal cord typically presents with symmetrical tingling and numbness in the hands and feet, progressing to weakness, unsteadiness, and cognitive changes. It can develop after as little as a single prolonged exposure (>6 hours) in patients with pre-existing B12 deficiency, or after repeated shorter exposures over weeks to months. Early recognition and treatment with hydroxocobalamin (vitamin B12) can lead to significant improvement, but delayed diagnosis may result in permanent neurological damage.
Nausea and vomiting are the most clinically significant common side effects, occurring more frequently in patients undergoing procedures with concurrent motion (such as during transport) or in those with a history of motion sickness. Administering nitrous oxide on an empty stomach and ensuring the patient is in a comfortable position can help minimize these effects. Anti-emetic medication may be administered prophylactically in high-risk patients.
How Should Medical Nitrous Oxide Be Stored?
Medical nitrous oxide is supplied as a compressed and partially liquefied gas in color-coded steel or aluminum cylinders. Proper storage is essential for safety and to maintain the pharmaceutical quality of the gas. Healthcare facilities must comply with national regulations for the storage of medical gases, which are classified as medicinal products under European and most international pharmaceutical legislation.
Storage conditions: Cylinders should be stored in a clean, dry, well-ventilated area at temperatures between −20°C and +50°C. They must be stored upright and properly secured (chained or strapped) to prevent falling. Cylinders should not be exposed to direct sunlight or placed near heat sources, radiators, or open flames. Nitrous oxide supports combustion, so storage areas must be kept free of oil, grease, and flammable materials.
Segregation requirements: Full and empty cylinders should be stored separately. Medical nitrous oxide cylinders must be stored apart from industrial gas cylinders and from cylinders containing flammable gases (such as cyclopropane). Clear labeling of storage areas is required to prevent mix-ups. Cylinders should not be stored in patient care areas unless they are in active use.
Cold weather considerations: Below approximately +4°C, the liquid phase of N₂O can separate from the gas phase in pre-mixed Entonox cylinders, resulting in delivery of oxygen-rich gas initially followed by dangerously hypoxic gas as the cylinder empties. Pre-mixed cylinders that have been exposed to freezing temperatures must be inverted several times to re-mix before use and should be stored above freezing for at least 24 hours before administration.
Cylinder integrity: Cylinders should be regularly inspected for damage, corrosion, and valve integrity. Expiry dates must be checked, and out-of-date cylinders returned to the supplier. The cylinder valve should be kept closed when not in use, and the dust cap should be in place during storage and transport. Any damaged or leaking cylinder should be moved to a well-ventilated outdoor area and the supplier notified immediately.
Security: Medical nitrous oxide has potential for recreational misuse. Storage areas should be locked and access restricted to authorized healthcare personnel. An inventory system should track cylinder movements and usage to detect any discrepancies promptly.
What Does Medical Nitrous Oxide Contain?
Medical nitrous oxide is a single-component pharmaceutical preparation. Unlike most medications, it contains no excipients, fillers, binders, preservatives, flavorings, or other inactive ingredients. The product is the purified gas itself, manufactured to meet pharmacopoeial standards.
Active Substance
- Name: Nitrous oxide (dinitrogen monoxide, N₂O)
- Chemical formula: N₂O
- Molecular weight: 44.01 g/mol
- CAS number: 10024-97-2
- Appearance: Colorless gas with a slightly sweet odor and taste
- Purity: Not less than 98.0% v/v (European Pharmacopoeia)
- Boiling point: −88.5°C at atmospheric pressure
- Critical temperature: 36.4°C (above this temperature, N₂O exists only as gas in the cylinder)
Impurity Limits (European Pharmacopoeia)
The pharmacopoeial monograph specifies maximum limits for potential impurities:
- Carbon monoxide (CO): Not more than 5 ppm
- Carbon dioxide (CO₂): Not more than 300 ppm
- Nitrogen monoxide (NO) and nitrogen dioxide (NO₂): Not more than 2 ppm (combined as NO₂)
- Water vapor: Dew point not exceeding −43°C
Pre-Mixed Formulations
In addition to pure N₂O, Nippon Gases and other medical gas suppliers provide pre-mixed formulations for specific clinical applications:
- 50% N₂O / 50% O₂ (Entonox equivalent): The most common pre-mixed product, widely used for labor analgesia and procedural pain relief. Supplied in cylinders at 137 bar pressure. Both components remain in the gas phase at temperatures above −7°C (the pseudocritical temperature of the mixture).
- Other N₂O/O₂ ratios: Less commonly, pre-mixed cylinders with different N₂O concentrations (e.g., 65% N₂O / 35% O₂) may be available for specialist anesthesia applications.
The gas cylinders used for medical nitrous oxide are manufactured from high-grade aluminum or steel alloys. Cylinder shoulders are color-coded blue (for N₂O) according to EN 1089-3 (European standard) or as specified by national regulations. Pre-mixed N₂O/O₂ cylinders have blue and white quartered shoulders. Pin-index or bullnose valve configurations prevent incorrect cylinder connections.
Frequently Asked Questions
Medical nitrous oxide (N₂O) is used for pain relief (analgesia) and mild sedation during medical and dental procedures. Common uses include labor pain management, dental treatments, emergency pain relief for fractures and burns, wound dressing changes, and as an adjunct to general anesthesia. It is typically self-administered as a 50:50 mixture with oxygen through a face mask or mouthpiece, providing rapid-onset pain relief within 2–5 minutes.
A 50% nitrous oxide/50% oxygen mixture (Entonox) is widely used and considered safe for labor pain relief. Decades of clinical experience and large observational studies show no increased risk of adverse neonatal outcomes. The mother remains conscious and in control throughout administration. However, nitrous oxide is generally avoided for elective procedures during the first trimester as a precautionary measure. The gas is rapidly eliminated from the body after use and does not require interruption of breastfeeding.
Prolonged or repeated nitrous oxide exposure (more than 6 hours continuously or frequent short exposures) can inactivate vitamin B12, leading to serious complications including megaloblastic anemia, peripheral neuropathy (numbness and tingling in hands and feet), subacute combined degeneration of the spinal cord, and cognitive impairment. These risks are significantly higher in patients with pre-existing B12 deficiency. Healthcare workers chronically exposed to trace levels may also experience reproductive health effects. Proper scavenging systems and monitoring are essential.
Nitrous oxide has one of the fastest onset-offset profiles of any analgesic. Pain relief begins within 2–5 minutes of starting inhalation and peaks at approximately 5 minutes. After stopping inhalation, effects wear off within 3–5 minutes as the gas is rapidly eliminated through the lungs. This rapid pharmacokinetic profile is due to its low blood-gas partition coefficient (0.47), meaning it does not dissolve extensively in the blood. Patients typically feel normal within minutes of discontinuation.
Nitrous oxide should not be used in patients with: pneumothorax or suspected pneumothorax, bowel obstruction, recent middle ear surgery, recent intraocular surgery involving gas injection (for up to 3 months), decompression sickness, severe COPD with air trapping, or significantly impaired consciousness. Patients with known vitamin B12 deficiency should only receive nitrous oxide after careful assessment of the risks and benefits. The gas must always be administered with at least 21% oxygen to prevent hypoxia.
Yes, nitrous oxide is widely and safely used in children aged 4 years and above for procedural analgesia and dental sedation. Children are often particularly good candidates because the non-invasive inhalation route avoids the need for needles, and the rapid onset and offset allow quick recovery. Younger children may need continuous-flow delivery rather than a demand valve if they cannot manage self-administration. Pediatric dosing concentrations are similar to adults, typically 30–50% N₂O in oxygen. A trained healthcare professional should always supervise administration in children.
References
This article is based on the following peer-reviewed sources and authoritative medical guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023. Nitrous oxide listed as an essential anesthetic agent.
- European Medicines Agency (EMA). Summary of Product Characteristics — Nitrous Oxide Medicinal Gas. European public assessment reports. Accessed January 2026.
- European Pharmacopoeia Commission. Nitrous Oxide Monograph (0416). European Pharmacopoeia, 11th Edition. Council of Europe; 2023.
- Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog. 2008;55(4):124-131. doi:10.2344/0003-3006-55.4.124
- Onody P, Gil P, Hennequin M. Safety of inhalation of a 50% nitrous oxide/oxygen premix: a prospective survey of 35,828 administrations. Drug Saf. 2006;29(7):633-640. doi:10.2165/00002018-200629070-00008
- National Institute for Health and Care Excellence (NICE). Intrapartum care for healthy women and babies. Clinical guideline CG190. Updated 2023. Includes nitrous oxide as a recommended labor analgesic option.
- Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707-722. doi:10.1097/ALN.0b013e3181870a17
- Garakani A, Jaffe RJ, Savla D, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. Am J Addict. 2016;25(5):358-369. doi:10.1111/ajad.12372
- American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 766: Approaches to Limit Intervention During Labor and Birth. Obstet Gynecol. 2019;133(2):e164-e173.
- British National Formulary (BNF). Nitrous oxide. National Institute for Health and Care Excellence (NICE); 2025. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in anesthesiology, pain medicine, and pharmacology. Our editorial process follows the GRADE evidence framework and adheres to international guidelines from WHO, EMA, and NICE.
Prepared by the iMedic Medical Editorial Team with specialization in anesthesiology and pharmacology. All medical claims are evidence-based and referenced to peer-reviewed literature.
Independently reviewed by the iMedic Medical Review Board. Content verified against European Pharmacopoeia, EMA SmPC data, WHO guidelines, and BNF recommendations.
Content follows iMedic Editorial Standards including conflict-of-interest declaration, transparency in funding sources, and adherence to the GRADE evidence framework.
This article is reviewed at least annually or when new significant evidence becomes available. Last review: January 19, 2026. Next scheduled review: January 2027.